CYBERMED LIFE - ORGANIC  & NATURAL LIVING

Dietary Modification - Low Carbohydrate-Ketogenic

Non-Toxic Metabolic Management of Metastatic Cancer in VM Mice: Novel Combination of Ketogenic Diet, Ketone Supplementation, and Hyperbaric Oxygen Therapy📎

Written by CYBERMED LIFE NEWS
Attachments:
Download this file (Non-Toxic Metabolic Management of Metastatic Cancer in VM Mice - Novel Combination of Ketogenic Diet, Ketone Supplementation, and Hyperbaric Oxygen Therapy..pdf)Non-Toxic Metabolic Management of Metastatic Cancer in VM Mice - Novel Combination of Ketogenic Diet, Ketone Supplementation, and Hyperbaric Oxygen Therapy..pdf[Non-Toxic Metabolic Management of Metastatic Cancer in VM Mice - Novel Combination of Ketogenic Diet, Ketone Supplementation, and Hyperbaric Oxygen Therapy.]5377 kB
facebook Share on Facebook
Abstract Title:

Non-Toxic Metabolic Management of Metastatic Cancer in VM Mice: Novel Combination of Ketogenic Diet, Ketone Supplementation, and Hyperbaric Oxygen Therapy.

Abstract Source:

PLoS One. 2015 ;10(6):e0127407. Epub 2015 Jun 10. PMID: 26061868

Abstract Author(s):

A M Poff, N Ward, T N Seyfried, P Arnold, D P D'Agostino

Article Affiliation:

A M Poff

Abstract:

The Warburg effect and tumor hypoxia underlie a unique cancer metabolic phenotype characterized by glucose dependency and aerobic fermentation. We previously showed that two non-toxic metabolic therapies - the ketogenic diet with concurrent hyperbaric oxygen (KD+HBOT) and dietary ketone supplementation - could increase survival time in the VM-M3 mouse model of metastatic cancer. We hypothesized that combining these therapies could provide an even greater therapeutic benefit in this model. Mice receiving the combination therapy demonstrated a marked reduction in tumor growth rate and metastatic spread, and lived twice as long as control animals. To further understand the effects of these metabolic therapies, we characterized the effects of high glucose (control), low glucose (LG), ketone supplementation (βHB), hyperbaric oxygen (HBOT), or combination therapy (LG+βHB+HBOT) on VM-M3 cells. Individually and combined, these metabolic therapies significantly decreased VM-M3 cell proliferation and viability. HBOT, alone or in combination with LG and βHB, increased ROS production in VM-M3 cells. This study strongly supports further investigation into this metabolic therapy as a potential non-toxic treatment for late-stage metastatic cancers.


We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.